Ipamorelin long term side effects: what the evidence shows

Last updated 2026-07-25

What does the research actually say about ipamorelin long term side effects?

The honest answer is that nobody has run a long-term human safety study on ipamorelin. The original characterization paper from 1998 described it as "the first selective growth hormone secretagogue," tested for its ability to release growth hormone without touching cortisol, prolactin, or other pituitary hormones ^[1]. That is a mechanism finding, not a safety finding, and it came from short-duration dosing. The closest thing to controlled human outcome data is a 2014 proof-of-concept trial in bowel resection patients, where ipamorelin was tested for a few days around surgery to see if it sped return of bowel function after postoperative ileus ^[2]. That trial answers a narrow question (does ipamorelin help gut motility after surgery) over a narrow window (days, not years). It says nothing about what happens if someone injects ipamorelin daily for two years. Recent review articles in orthopaedic and sports medicine journals have started cataloguing peptide use in athletes and patients, but they consistently flag the same gap. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons on therapeutic peptides in orthopaedics discusses applications and open questions without citing long-term human safety data for ipamorelin specifically ^[3]. A companion primer in the American Journal of Sports Medicine for orthopaedic and sports medicine physicians makes a similar point: injectable peptides are moving into clinical and semi-clinical use faster than the safety literature is catching up ^[4]. If you're looking for a study that followed people on ipamorelin for a year or more and reported adverse events, it does not exist in the indexed literature as of this writing.

Is ipamorelin safe to use for months or years at a time?

Nobody can answer that with real data, and that itself is the answer worth knowing. What exists is short human pharmacokinetic work, some animal studies running weeks to a few months, and a handful of disease-specific human trials (cancer cachexia, postoperative ileus) that were not designed to catch rare or slow-building harms. A 2026 Sports Medicine review on approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance groups ipamorelin with other secretagogues used off-label by athletes, and it treats long-term safety as an open question rather than a settled one ^[5]. A separate 2026 review in the JBJS covering injectable peptides in sports medicine frames the antidoping and safety picture the same way: use has outpaced evidence ^[6]. The rat literature gives some texture. In young female rats, chronic ipamorelin treatment produced measurable changes in the somatotroph (growth-hormone-producing) cells of the pituitary when examined afterward ^[7]. Separately, ipamorelin increased longitudinal bone growth in growing rats ^[8] and increased bone mineral content in adult female rats when paired with another secretagogue ^[9]. These are real, replicated findings in animals. They are not proof of a specific human long-term risk, but they tell you the compound does things to bone and pituitary tissue over sustained dosing, which is exactly the kind of effect you'd want tracked in a multi-year human study that does not exist yet.

What side effects has ipamorelin actually caused in trials?

In the studies that do exist, the side effect profile is generally mild and mechanistically consistent with growth hormone release. The 1998 selectivity paper is notable mainly for what ipamorelin did not do: it did not meaningfully raise cortisol or prolactin at the doses tested, unlike some older GH-releasing peptides ^[1]. That selectivity is the whole reason ipamorelin got attention in the first place. Pharmacokinetic-pharmacodynamic modeling in human volunteers from 1999 characterized how ipamorelin dose relates to GH release curves, giving researchers a model for predicting GH response but not a safety endpoint list ^[10]. A separate 1998 pharmacokinetic paper looked at nasal absorption of ipamorelin and related peptides, relevant to formulation but again not a long-term safety readout ^[11]. On the metabolic side, animal work shows ipamorelin engages insulin physiology. A 2004 paper in Neuroendocrinology Letters described the mechanism by which ipamorelin evokes insulin release from the pancreas in normal and diabetic rats ^[12], and a 2001 paper found GH secretagogues, including this class, can stimulate adiposity through GH-independent pathways ^[13]. Translation: this is not a hormone that only does one clean thing. It intersects with insulin signaling and fat tissue biology in ways that matter for anyone with existing metabolic disease, and that intersection has not been mapped in long-term human use.

Does ipamorelin affect blood sugar or insulin over time?

There is a documented mechanism by which ipamorelin triggers insulin release from the pancreas, shown in both normal and diabetic rats ^[12]. That is a direct, mechanistic finding, not a guess. What it means for someone using ipamorelin for months, especially someone with prediabetes or type 2 diabetes, has not been studied in a dedicated long-term human trial. Growth hormone itself is well known clinically to push blood sugar upward and reduce insulin sensitivity when elevated chronically, which is part of why growth hormone secretagogues get metabolic scrutiny in the first place. A 2009 study on GH and GH secretagogue effects on nitrogen balance and urea synthesis in steroid-treated rats adds another data point: GH secretagogues alter protein and nitrogen metabolism, more than glucose handling ^[14]. If you have any personal or family history of glucose intolerance, that's a conversation for a prescriber before starting, not an afterthought.

Can ipamorelin cause problems with bones or joints long term?

The animal data on bone is actually some of the more consistent evidence in the ipamorelin literature, and it cuts both directions. Ipamorelin increased longitudinal bone growth in young rats ^[8], increased bone mineral content in adult female female rats when combined with GHRP-6 ^[9], and counteracted glucocorticoid-induced loss of bone formation in adult rats ^[15]. That last finding is genuinely interesting: it suggests a protective mechanism against steroid-induced bone loss, at least in a rat model. None of this has been replicated in a long-term human bone density study. Rat bone biology and human bone biology overlap but are not identical, and glucocorticoid-treated rats are a specific disease model, not a stand-in for a healthy adult using ipamorelin for general purposes. If you're asking whether ipamorelin builds or protects human bone over years of use, the honest answer is: it does something to bone in animals, and nobody has checked in people over the long term.

What about cancer risk with long term GH secretagogue use?

This is the question that gets asked the most and answered the least. Growth hormone and IGF-1 pathways are involved in cell growth signaling, which is exactly why oncologists watch GH axis activity in cancer survivors. The available ipamorelin-specific data on cancer comes from a different angle than most people expect: a 2024 study in Physiology & Behavior found that ipamorelin (along with anamorelin) inhibited cisplatin-induced weight loss in ferrets, a cachexia model, with anamorelin also showing anti-emetic effects through a central mechanism ^[16]. That's a study of ipamorelin helping counteract wasting during cancer treatment, not a study of ipamorelin causing cancer. It's an important distinction and also a reminder that the literature on ipamorelin and cancer biology is thin and mostly indirect. Nobody has published a long-term epidemiological study tracking cancer incidence in people using ipamorelin for years. Given that GH and IGF-1 pathways are biologically active in tumor growth signaling generally, this is a gap worth naming explicitly rather than waving away.

Does ipamorelin cause pain or gut symptoms with repeated use?

Some of the strongest ipamorelin efficacy data actually comes from the gut, not from bodybuilding contexts. A 2014 randomized, controlled trial tested ipamorelin in bowel resection patients for postoperative ileus and found it moved the compound from animal proof-of-concept toward human evidence for a specific surgical indication ^[2]. Rodent studies backed this up mechanistically: ipamorelin improved gastric dysmotility in a rat model of postoperative ileus ^[17] and showed efficacy in a separate rodent ileus model published in the Journal of Pharmacology and Experimental Therapeutics ^[18]. On pain, a 2020 paper in the Journal of Experimental Pharmacology looked at ghrelin mimetics, the drug class ipamorelin belongs to, and found effects on visceral and somatic nociception (pain signaling) ^[19]. This is preliminary mechanistic work, useful for understanding what receptor pathway ipamorelin sits in, not a statement that ipamorelin treats or causes chronic pain in people using it long-term for other reasons.

How is ipamorelin different from real growth hormone in terms of risk?

Ipamorelin does not directly inject growth hormone into the body. It stimulates the pituitary's own ghrelin receptor (GHSR-1a) to release GH in a pulsatile pattern, which is theoretically gentler on the feedback loop than exogenous GH. The original 1998 paper describing it as the first selective GH secretagogue is built around this exact idea: selectively pulse GH release without dragging cortisol and prolactin along for the ride ^[1]. A related line of medicinal chemistry work from the same era developed a series of highly potent GH-releasing peptides derived from the ipamorelin scaffold ^[20], and another 1998 paper in the Journal of Medicinal Chemistry described novel orally active GH secretagogues in the same family ^[21]. This chemistry lineage matters because it shows ipamorelin was designed, deliberately, to be more selective than earlier peptides like GHRP-6. Selective does not mean risk-free. It means the risk profile is different from raw HGH, not smaller by definition, and that difference has not been quantified over long-term human use either. For people comparing this class of drug to other GH-axis options, ibutamoren vs ipamorelin covers the practical differences in route, half-life, and receptor activity between an oral secretagogue and an injectable one.

Does the ipamorelin/tesamorelin blend used in practice change the safety picture?

Worth being direct about a market reality here: there is no standalone ipamorelin product available through legitimate compounding channels. Ipamorelin is dispensed as part of a tesamorelin/ipamorelin blend, combining a GHRH analog (tesamorelin) with a ghrelin-receptor secretagogue (ipamorelin) to work on two different steps of the GH release pathway. This matters for the long-term side effect question because almost none of the studies cited above tested that combination. The 1998 ipamorelin selectivity paper tested ipamorelin alone ^[1]. The postoperative ileus trial tested ipamorelin alone ^[2]. Tesamorelin has its own separate evidence base, mostly built around HIV-associated lipodystrophy, and combining it with ipamorelin changes the pharmacodynamics in ways the single-agent literature can't predict. Ipamorelin Co works with a provider-reviewed dispensing process through a licensed pharmacy partner precisely because this combination needs a prescriber who understands both halves of the blend, not a self-directed purchase based on forum dosing charts. Anyone reading dosing protocols online should know that most of what circulates about "ipamorelin cycles" and stacking schedules comes from bodybuilding forums, not from the pharmacology literature. The peer-reviewed data describe single doses or short courses measured in days to weeks. The forum protocols describe multi-month or indefinite use. Those two things are not the same evidence base, and treating forum consensus as if it were clinical data is exactly the gap this article is trying to close.

What does regulatory status tell you about the safety evidence?

Ipamorelin is not an FDA-approved drug. You will not find it in the Drugs@FDA database of approved products ^[22]. It exists in the U.S. market through the compounding pathway governed by 21 U.S.C. 353a, which allows licensed pharmacies to compound drugs from bulk substances under specific conditions ^[23]. The FDA maintains lists of bulk drug substances that can be used under 503A compounding (the section 216.23 bulks list) ^[24] and under 503B outsourcing facility compounding (the section 216.24 bulks list) ^[25], and it separately maintains a running list of substances nominated for compounding use that have not yet been categorized ^[26]. The FDA's own compounding guidance page describes this framework explicitly as covering bulk drug substances used in compounding under section 503A ^[27]. None of this regulatory apparatus is a safety endorsement. Compounding pathway status tells you a pharmacy can legally prepare the substance under certain conditions; it does not tell you the substance has cleared the same efficacy and long-term safety review that an FDA-approved drug goes through via a New Drug Application. That's a meaningful distinction for anyone assuming "available at a compounding pharmacy" means "proven safe long-term." It does not.

How should someone weigh the risk if they still want to try it?

Given the state of the evidence, the reasonable approach is to treat ipamorelin (as part of the tesamorelin/ipamorelin blend) the way you'd treat any compounded, off-label peptide with thin long-term data: short courses, real monitoring, and a prescriber who is actually reviewing your labs, not rubber-stamping a request. That means baseline and periodic bloodwork covering fasting glucose or HbA1c (given the documented insulin mechanism ^[12]), IGF-1 levels to gauge GH axis response, and a real conversation about personal or family cancer history given the unresolved questions around GH/IGF-1 signaling and tumor biology. It means not assuming that because a rat study showed a bone benefit ^[8][9][15], the same benefit applies to your specific situation. And it means being skeptical of any source, including bodybuilding forums, that presents multi-year dosing protocols as though they were validated by the literature you've just read through. For practical procedural questions once you and a provider have decided to move forward, see ipamorelin dosage for how protocols are typically structured, ipamorelin how to inject and ipamorelin injection sites for administration basics, ipamorelin half life for how the drug clears the body, and does ipamorelin need to be refrigerated for storage handling that affects potency and, indirectly, dosing accuracy.

Frequently asked questions

Has anyone studied ipamorelin for more than a year in humans?

No published trial has followed human subjects on ipamorelin for a year or longer. The available human data come from short pharmacokinetic studies and a postoperative ileus trial lasting days ^[2][10]. Long-term human safety data simply do not exist yet in the indexed literature.

Can ipamorelin cause cancer with long-term use?

There is no human study showing ipamorelin causes cancer. The closest cancer-related data is a 2024 ferret study where ipamorelin reduced cisplatin-induced weight loss during cancer treatment ^[16], which is about counteracting cachexia, not about cancer risk. Given GH/IGF-1's known role in cell growth signaling, this remains an open question, not a resolved one.

Does ipamorelin raise blood sugar over time?

Ipamorelin has a documented mechanism for triggering insulin release from the pancreas in rat studies ^[12]. Whether repeated human use meaningfully shifts blood sugar or insulin sensitivity long-term has not been studied directly, so anyone with glucose intolerance should get baseline and follow-up labs with a prescriber.

Is ipamorelin FDA approved?

No. Ipamorelin is not listed in the FDA's Drugs@FDA database of approved products ^[22]. It is available in the U.S. only through the compounding pathway under 21 U.S.C. 353a ^[23], which is a legal manufacturing framework, not a safety or efficacy approval.

What are the most common short-term side effects reported?

Controlled studies emphasize that ipamorelin is selective for GH release without significantly raising cortisol or prolactin, unlike older secretagogues ^[1]. Documented effects in the literature relate to gut motility ^[2][17][18], insulin release ^[12], and bone metabolism ^[8][9][15], rather than a long list of adverse events, because most studies were short and narrowly focused.

Can ipamorelin affect bone density permanently?

Animal studies show ipamorelin increases longitudinal bone growth in young rats ^[8] and bone mineral content in adult female rats ^[9], and it counteracted glucocorticoid-induced bone loss in another rat study ^[15]. No long-term human bone density study exists, so permanence in humans is unconfirmed.

Why is there so little long-term data on ipamorelin?

Ipamorelin was developed and characterized mainly in the late 1990s as a research compound and later studied for narrow clinical uses like postoperative ileus ^[1][2]. It never went through the multi-year Phase III trial process required for FDA approval, so the safety database that exists for approved GH-axis drugs was never built for ipamorelin specifically.

Is the ipamorelin sold today the same as what was studied in the 1990s?

The molecule is the same peptide characterized in 1998 ^[1], but today it is not sold as a standalone product. It is dispensed as part of a tesamorelin/ipamorelin blend through compounding pharmacies, a combination that has not itself been directly studied in the single-agent papers cited throughout this article.

Does combining ipamorelin with tesamorelin change the safety profile?

It likely does, since the two peptides act on different steps of GH release, but there is no dedicated long-term safety study of the combined blend in the literature reviewed here. Each peptide has its own separate evidence base, and combining them changes pharmacodynamics in ways the single-agent studies cannot predict.

Can ipamorelin cause pain or gut side effects?

The evidence points the other direction for gut symptoms: ipamorelin has shown benefit for postoperative ileus and gastric dysmotility in rodent and human proof-of-concept studies ^[2][17][18]. Separate mechanistic work on ghrelin mimetics and pain signaling exists ^[19], but it does not describe ipamorelin causing chronic pain.

What labs should someone get if using ipamorelin long-term?

Given documented mechanisms affecting insulin ^[12] and the GH/IGF-1 axis generally, reasonable monitoring includes fasting glucose or HbA1c, IGF-1 levels, and a review of personal or family cancer history with a prescriber. No formal monitoring protocol has been validated in a long-term trial, so this is a risk-management approach, not an evidence-backed schedule.

Where does most of the ipamorelin long-term dosing information online come from?

Most multi-month or indefinite dosing protocols circulating online originate in bodybuilding forums, not peer-reviewed research. The published literature covers single doses or courses lasting days to a few weeks ^[1][2][10]. Treating forum consensus as equivalent to clinical evidence is a common and risky mistake.

Sources

1. European Journal of Endocrinology, 1998 (PMID 9849822): Ipamorelin is described as the first selective growth hormone secretagogue, releasing GH without significantly raising cortisol or prolactin.
2. International Journal of Colorectal Disease, 2014 (PMID 25331030): A randomized, controlled proof-of-concept trial tested ipamorelin in bowel resection patients for postoperative ileus management.
3. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Review of therapeutic peptides in orthopaedics covering applications, challenges, and future directions, including evidence gaps.
4. American Journal of Sports Medicine, 2026 (PMID 41476424): Primer for orthopaedic and sports medicine physicians on injectable peptide therapy use outpacing safety evidence.
5. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): Review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance groups ipamorelin among compounds with unresolved long-term safety questions.
6. JBJS Reviews, 2026 (PMID 42160466): Structured narrative review of injectable peptides in sports medicine covering evidence, safety, and antidoping implications.
7. Histology and Histopathology, 2002 (PMID 12168778): Chronic ipamorelin treatment in young female rats produced measurable changes in pituitary somatotroph cells.
8. Growth Hormone & IGF Research, 1999 (PMID 10373343): Ipamorelin induced longitudinal bone growth in rats.
9. Journal of Endocrinology, 2000 (PMID 10828840): Ipamorelin and GH-releasing peptide-6 increased bone mineral content in adult female rats.
10. Pharmaceutical Research, 1999 (PMID 10496658): Pharmacokinetic-pharmacodynamic modeling of ipamorelin characterized dose-response GH release curves in human volunteers.
11. Xenobiotica, 1998 (PMID 9879640): Pharmacokinetic evaluation of ipamorelin and related peptides examined nasal absorption.
12. Neuroendocrinology Letters, 2004 (PMID 15665799): Described the mechanism by which ipamorelin evokes insulin release from the pancreas in normal and diabetic rats.
13. Biochemical and Biophysical Research Communications, 2001 (PMID 11162489): GH secretagogues can stimulate adiposity through growth-hormone-independent pathways.
14. Growth Hormone & IGF Research, 2009 (PMID 19231263): GH and GH secretagogue effects on nitrogen balance and urea synthesis were studied in steroid-treated rats.
15. Growth Hormone & IGF Research, 2001 (PMID 11735244): Ipamorelin counteracted glucocorticoid-induced decrease in bone formation in adult rats.
16. Physiology & Behavior, 2024 (PMID 39043357): Ipamorelin and anamorelin inhibited cisplatin-induced weight loss in ferrets, with anamorelin also showing anti-emetic effects.
17. Journal of Experimental Pharmacology, 2012 (PMID 27186127): Ipamorelin improved gastric dysmotility in a rodent model of postoperative ileus.
18. Journal of Pharmacology and Experimental Therapeutics, 2009 (PMID 19289567): Ipamorelin showed efficacy in a rodent model of postoperative ileus.
19. Journal of Experimental Pharmacology, 2020 (PMID 32801950): Ghrelin mimetics, the class ipamorelin belongs to, showed effects on visceral and somatic pain signaling.
20. Journal of Medicinal Chemistry, 1998 (PMID 9733495): A series of highly potent growth hormone-releasing peptides was derived from the ipamorelin scaffold.
21. Journal of Medicinal Chemistry, 1998 (PMID 9733496): Describes novel orally active growth hormone secretagogues developed in the same chemical family as ipamorelin.
22. Drugs@FDA, FDA-approved drug products database: Ipamorelin does not appear in the FDA's database of approved drug products.
23. 21 U.S.C. 353a, pharmacy compounding: Establishes the legal pathway allowing licensed pharmacies to compound drugs from bulk substances under specific conditions.
24. 21 CFR 216.23, the final 503A Bulks List: Lists bulk drug substances that may be used in compounding under section 503A.
25. 21 CFR 216.24, the 503B Bulks List: Lists bulk drug substances that may be used in compounding under section 503B by outsourcing facilities.
26. FDA, bulk drug substances nominated for use in compounding (current list): Maintains a running list of substances nominated for compounding use pending categorization.
27. FDA, bulk drug substances used in compounding under section 503A: FDA guidance describes the framework governing bulk drug substances used in compounding under section 503A.